Management of inflammatory bowel disease in the elderly: Do biologicals offer a better alternative?

HaC.; KatzS.

首页> 外文期刊>Drugs and aging >Management of inflammatory bowel disease in the elderly: Do biologicals offer a better alternative?

【24h】

Management of inflammatory bowel disease in the elderly: Do biologicals offer a better alternative?

机译：老年人炎症性肠病的管理：生物制剂是否提供更好的选择？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The management of inflammatory bowel disease (IBD) in elderly patients provides added complexity for healthcare providers who need to take into account the high likelihood of co-morbid disease, the need for polypharmacy and, in many instances, greater patient fragility. While biologics are often considered first-line corticosteroid-sparing strategies for moderate to severe disease, the additional variables unique to an elderly patient warrant consideration when discussing IBD therapeutics. As chronic corticosteroid use, although relatively common among older IBD patients, is suboptimal, the efficacy and safety of biologics compared with immunomodulators among older IBD patients needs additional investigation.

机译：老年患者的炎症性肠病（IBD）的管理为医疗服务提供者增加了复杂性，他们需要考虑到合并病的高可能性，多药店的需要以及在许多情况下患者的更大脆弱性。虽然生物制剂通常被认为是中度至重度疾病的一线皮质激素治疗策略，但在讨论IBD治疗方法时，应考虑老年患者特有的其他变量。由于慢性皮质类固醇的使用虽然在老年IBD患者中相对普遍，但次优，因此与免疫调节剂相比，在老年IBD患者中使用生物制剂的疗效和安全性需要进一步研究。

著录项

来源
《Drugs and aging》 |2013年第11期|共6页
作者
HaC.; KatzS.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Management of inflammatory bowel disease in the elderly: Do biologicals offer a better alternative? [J] . HaC., KatzS. Drugs and aging . 2013,第11期

机译：老年人炎症性肠病的管理：生物制剂是否提供更好的选择？
2. Elderly versus Non-elderly Patients with Inflammatory Bowel Disease on Biologic Therapy: Characteristics and Outcomes [J] . Lin Steven, Devore Zachary, Wang Christina, The American Journal of Gastroenterology . 2018,第Suppla2期

机译：老年人对非老年患者生物治疗的炎症性肠病：特征和结果
3. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics [J] . DevlinS.M., BresslerB., BernsteinC.N., Canadian journal of gastroenterology . 2013,第10期

机译：用于治疗肠炎的后续进入生物制剂概述和加拿大胃肠病学协会关于后续进入生物制剂的立场声明
4. Natural anti-Inflammatory Compounds for the Management and Adjuvant Therapy of Inflammatory Bowel Disease (IBD) and its Drug Delivery System(DDS) for Targeted to Colon. [C] . Annual meeting exposition of the Controlled Release Society . 2009

机译：用于炎症性肠病（IBD）的管理和佐剂治疗的天然抗炎化合物及其药物递送系统（DDS）用于靶向结肠。
5. The Impact of Coping Strategies Exercised by Children and Their Families on Clinical Management, Disease Outcome, and Emotional Well-Being in Children with Newly Diagnosed Inflammatory Bowel Disease [D] . Collins, Derek Alexander. 2019

机译：儿童及其家庭行使的应对策略对临床管理，疾病结果以及新诊断的炎症性肠病患儿的临床管理，疾病结果和情感福祉
6. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics [O] . Shane M Devlin, Brian Bressler, Charles N Bernstein, 2013

机译：用于治疗肠炎的后续生物制剂概述和加拿大胃肠病学协会关于后续生物制剂的立场声明
7. P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases [O] . M Attauabi, C Höglund, J Fassov, 2021

机译：P347 vedolizumab作为老年人生物治疗禁忌患者反对抗TNF疗法 - 一个真正的全球全球全国炎症肠疾病患者

Management of inflammatory bowel disease in the elderly: Do biologicals offer a better alternative?

摘要

著录项

相似文献

相关主题

期刊订阅